[Recent advance in adjuvant therapy for breast cancer]
- PMID: 12506467
[Recent advance in adjuvant therapy for breast cancer]
Abstract
Adjuvant systemic therapy has contributed to a significant improvement of disease-free and overall survival in addition to surgery and irradiation to the local disease. The adjuvant therapy to a patient is determined integrating the information on estimated risk of recurrence, benefit and harm of the therapy and the patient's value. In this review, the state of the art of adjuvant therapy is discussed from several aspects, such as interpretation and evaluation of risk, the best available evidences on adjuvant systemic therapy, the future direction of primary therapy for breast cancer, and patient-oriented decision making.
Similar articles
-
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].Gan To Kagaku Ryoho. 2006 Oct;33(10):1423-9. Gan To Kagaku Ryoho. 2006. PMID: 17033231 Clinical Trial. Japanese.
-
[Benefits of adjuvant chemotherapy for breast cancer].Gan To Kagaku Ryoho. 1997 Aug;24(10):1239-44. Gan To Kagaku Ryoho. 1997. PMID: 9279342 Japanese.
-
[Adjuvant therapy of breast cancer].Khirurgiia (Mosk). 2001;(5):52-60. Khirurgiia (Mosk). 2001. PMID: 11505673 Review. Russian. No abstract available.
-
Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.J Clin Oncol. 2005 Apr 1;23(10):2172-84. doi: 10.1200/JCO.2005.02.158. J Clin Oncol. 2005. PMID: 15800310 Clinical Trial.
-
Adjuvant systemic therapy in primary breast cancer.Acta Chir Scand Suppl. 1984;519:43-53. Acta Chir Scand Suppl. 1984. PMID: 6393664 Review. No abstract available.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical